Skip to content

v0.5.1 (Alpha)

Choose a tag to compare

@Fr4n0b Fr4n0b released this 12 Nov 17:45
· 20 commits to main since this release

SYNAPTIK v0.5.1: Translational Fluid Biomarker & Patient Stratification Panel

This release bridges in vitro disease model findings directly to clinical fluid biomarkers (Neurofilament Light Chain, NfL) and patient cohort stratification for clinical trial optimization.

Highlights

  • synaptik biomarker CLI command & API:
    • Models longitudinal in vivo biomarker suppression (plasma and CSF NfL via Simoa ultrasensitive assay) from in vitro axonal rescue percentages.
    • Implements clearance pharmacodynamics ($t_{1/2} = 8\text{ weeks}$, translation scaling factor $\beta = 0.72$), projecting suppression curves at Weeks 4, 8, 12, 16, 24, 36, and 48.
    • Benchmarked against clinical trial precedents: VALOR study (SOD1 tofersen, Miller et al. NEJM 2022: ~60% plasma NfL suppression; FDA Accelerated Approval surrogate endpoint framework).
  • Clinical trial patient stratification & cohort optimization:
    • Classifies patients into progression tiers (fast, intermediate, slow) based on baseline plasma NfL cutoffs ($> 75\text{ pg/mL}$, $40\text{--}75\text{ pg/mL}$, $< 40\text{ pg/mL}$).
    • Computes trial power and sample size requirements: demonstrates that biomarker-enriched patient stratification reduces required patient cohort size per arm by 60–75% (e.g. from 74 down to 18 patients/arm) to detect 30% therapeutic slowing of functional decline (ALSFRS-R).
  • Test coverage:
    • 21 new regression checks in tests/test_biomarker.py, bringing the total platform test suite to 321 passing checks across Python 3.10, 3.11, and 3.12.